Simon Greenwood

Simon Greenwood is a Senior Investment Director at Roche Venture Fund who recently joined the Board of Directors at COUR Pharmaceuticals.12 His appointment to the board came in connection with COUR's $105 million Series A financing round, which closed in January 2024.1

In his professional capacity, Greenwood holds the following positions:

1. Senior Investment Director at Roche Venture Fund12
2. Board Member at COUR Pharmaceuticals Development Company, Inc.34
3. Vice President of Venture Investing at Roche Venture Fund56

Greenwood's involvement with COUR Pharmaceuticals is part of a larger investment strategy. The Series A financing round he participated in was co-led by Lumira Ventures and Alpha Wave Ventures, with additional participation from other prominent investors including Roche Venture Fund, Pfizer, Bristol Myers Squibb, Angelini Ventures, and the JDRF T1D Fund.12

COUR Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapies for autoimmune and inflammatory diseases. The company's approach involves using a proprietary antigen-specific immune tolerance platform to reprogram the immune system and address the root causes of immune-mediated diseases.12

Greenwood's role on the board is likely to involve providing strategic guidance and leveraging his experience in venture investing to support COUR's development of innovative treatments for conditions such as Myasthenia Gravis, Type 1 Diabetes, Celiac Disease, and Primary Biliary Cholangitis.12